Former Queen's University spin-out using its unique AI-driven drug discovery engine to fight aggressive cancers ...

Cancer is not going away. As the U.S. population ages, the burden of cancer on society will only grow. Disparities in treatment access and outcomes persist across race, income and geography. And ...

Cancer completely disappeared from two-thirds of 24 patients treated with a combination of the antibody petosemtamab and ...

Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women ...

Seeking to enhance its presence in cancer drugs and the US, the German drug company Merck KGaA is buying the oncology biotech SpringWorks Therapeutics for $3.9 billion. The deal is expected to ...

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the ...

UroGen Pharma reports strong long-term data for Jelmyto and UGN-102 in cancer studies and shares promising early results for ...

suggesting these targets as potential biomarkers,” stated Purple Biotech VP R&D Dr. Hadas Reuveni. “STAT3 and b-catenin, as well as cancer stem cells, are major immune evasion and tumor ...

MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and ...

Under the agreement, Er-Kim is appointed as the distribution partner for NERLYNX in Armenia, Azerbaijan, Belarus, Georgia, ...

SAN DIEGO and CALGARY, AB, April 24, 2025 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will ...